Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents
about
Prostate-specific membrane antigen as a target for cancer imaging and therapyA remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules.Molecular imaging: current status and emerging strategies.Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.GCPII imaging and cancer.Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.A targeted low molecular weight near-infrared fluorescent probe for prostate cancer.(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors.New agents and techniques for imaging prostate cancer.Anti-tumor effects of a recombinant anti-prostate specific membrane antigen immunotoxin against prostate cancer cells.[(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA)Mutation at the folate receptor 4 locus modulates gene expression profiles in the mouse uterus in response to periconceptional folate supplementation.Functional prostate-specific membrane antigen is enriched in exosomes from prostate cancer cellsPreclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.Putative molecular signatures for the imaging of prostate cancer.The evolution of imaging in cancer: current state and future challenges.Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancerPET imaging in prostate cancer: focus on prostate-specific membrane antigen⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer.Small-molecule PSMA ligands. Current state, SAR and perspectives.Current use of PSMA-PET in prostate cancer management.Small Molecules for Active Targeting in Cancer.Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis.Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker.Radiofluorination of PSMA-HBED via Al(18)F(2+) Chelation and Biological Evaluations In Vitro.Metal-Based PSMA Radioligands.A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA).2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.Imaging prostate cancer lymph node metastases with a multimodality contrast agent.68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer.A low molecular weight PSMA-based fluorescent imaging agent for cancer.Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer.A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer.Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate CancerPSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responsesEffect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).PSMA as a target for radiolabelled small molecules.Radiochemistry and Preclinical PET Imaging of 68Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane Antigen.Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.
P2860
Q26799439-90C51A0A-52CF-4C69-97E5-1852F3CA5554Q27664106-FDFBAEBE-0074-48AA-9829-80DFF5B8E86AQ30474579-D6074861-9788-4950-B28A-A90542196FA6Q33699158-96D83BBE-C220-4AF1-8921-B6BBF2ABA8F4Q33827632-3E013F5F-DC7A-4B4B-9F0C-6DDD7AF16351Q34284930-28865A6C-FDEA-4BC0-B8F8-10090303B239Q35446801-A1CF8593-D9BD-433A-9069-FCB647D2ED5EQ35877470-1B6E1327-67F7-41C0-8115-06151B8D0BDBQ35911784-50730DD0-E4A4-4E99-B9A0-E1CD5E6B8AD2Q36279293-EC8A9B05-9F63-4EA8-94F4-B31269F79200Q36867784-378FF276-A917-45B9-A171-4292B69A813CQ37163333-65569B85-55C1-4F42-9233-F865AAB19EB7Q37591940-BD6B9B85-1728-4DA3-9A8D-82C317708FBFQ37623394-EAC8D0FE-5DB9-4801-B415-AB7874073DC9Q37656266-E999B624-ADB1-4C7F-861F-EFC7CEB3B667Q37848518-9E457207-8173-428A-A1AD-637C9BB128EEQ37972920-FAE4AF41-5BC9-4C7E-82B4-B6351E1F0B98Q38099369-6E88D7EA-01AE-48B5-8485-06314078F3AEQ38705627-23865B16-421E-4FF2-B110-26C9E6DECAC0Q38737674-1C033D32-75F4-4BC0-BECA-0DF6E2D3AC4EQ38744524-51E4C89B-18C7-43E4-BF34-52DF037690E2Q38780383-D67D427C-23B4-4F6A-B043-BB2A058280C2Q38821290-0701A138-B129-4B58-9E7C-22E6C1BD3C07Q39016659-8BA5D5D2-BE35-4A28-A4A7-B047F573DD26Q39018543-1A382439-CDE7-4395-BE3F-D000C8C99272Q39198527-9AA772EB-6571-4861-92D5-3C0E3DEEEB6DQ39420655-BA68309A-1472-4585-A636-53BBCC69EA56Q39449818-CB29F12D-F95D-495F-8CE0-E52332948BECQ39549282-1280232C-026B-442A-841C-CA74573C8372Q39689821-2522BE87-43D7-4C18-AEBA-F392E888ACDDQ39789211-F6864682-AB3A-4059-9D27-E4A12F66D516Q39808317-C062520E-DDA0-4E47-B655-6A519DE6BC67Q41582278-5E12EDBE-7252-44DB-9799-DD27894A0A49Q41600550-5276798E-7063-4F1B-B76B-ADD47A6A1579Q41905456-0EDF721F-E897-41C5-8911-0A78EA47702AQ42114642-F4CECA0C-5C9B-4E81-9D0D-A455C22D7404Q42620151-C219B6C3-5911-4AE5-A8F3-B6F189074127Q43177005-49660ABC-7E63-46A7-BD01-C2E7411538F2Q45753373-19526AB3-D214-4569-8A72-952CD50900A7Q48905216-47278D9A-D43B-4525-A1C1-4379A249EF39
P2860
Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Design, synthesis, and preclin ...... ed (99m)Tc-radioimaging agents
@ast
Design, synthesis, and preclin ...... ed (99m)Tc-radioimaging agents
@en
Design, synthesis, and preclin ...... ed (99m)Tc-radioimaging agents
@nl
type
label
Design, synthesis, and preclin ...... ed (99m)Tc-radioimaging agents
@ast
Design, synthesis, and preclin ...... ed (99m)Tc-radioimaging agents
@en
Design, synthesis, and preclin ...... ed (99m)Tc-radioimaging agents
@nl
prefLabel
Design, synthesis, and preclin ...... ed (99m)Tc-radioimaging agents
@ast
Design, synthesis, and preclin ...... ed (99m)Tc-radioimaging agents
@en
Design, synthesis, and preclin ...... ed (99m)Tc-radioimaging agents
@nl
P2093
P356
P1476
Design, synthesis, and preclin ...... ed (99m)Tc-radioimaging agents
@en
P2093
Carol B Post
Philip S Low
Sumith A Kularatne
Zhigang Zhou
P304
P356
10.1021/MP9000712
P407
P577
2009-01-01T00:00:00Z